Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: PLX3397|DRUG: Eribulin
Sponsor: Hope Rugo, MD
Collaborators: Susan G. Komen Breast Cancer Foundation|Plexxikon